Characterization of commercially available vaginal lubricants: A safety perspective

Pharmaceutics

Volumn 6, Issue 3, 2014, Pages 530-542

  Cunha, Ana Raquel ^a   Machado, Rita M ^a,b   Palmeira de Oliveira, Ana ^a,b   Martinez de Oliveira, José ^a,c   Neves, José Das ^e   Palmeira de Oliveira, Rita ^a,b,c  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b Edifício UBIMEDICAL Estrada Municipal 506   (Portugal)

^c Centro Hospitalar da Cova da Beira   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^e INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

Buffer capacity; Cytotoxicity; Microbicides; Osmolality; Vaginal drug delivery

Indexed keywords

HYDROXYETHYLCELLULOSE; LACTATE DEHYDROGENASE; LUBRICATING AGENT; NONOXINOL 9; PLACEBO; SORBIC ACID; UNCLASSIFIED DRUG; VAGINAL LUBRICANT AGENT;

ARTICLE; CELL ASSAY; CONDOM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; GEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; OSMOLALITY; PH; TOXICITY TESTING; VAGINAL LUBRICATION;

EID: 84937029060     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics6030530     Document Type: Article

References (45)

1. das Neves, J.; Amaral, M.H.; Bahia, M.F. Vaginal drug delivery. In Pharmaceutical Manufacturing Handbook: Production and Processes; Gad, S.C., Ed.; Wiley: Hoboken, NJ, USA, 2008; pp. 809–878.
2. das Neves, J.; Palmeira-de-Oliveira, R.; Palmeira-de-Oliveira, A.; Rodrigues, F.; Sarmento, B. Vaginal mucosa and drug delivery. In Mucoadhesive Materials and Drug Delivery Systems; Khutoryanskiy, V.V., Ed.; Wiley: Chichester, UK, 2014; pp. 99–131.
3. Braunstein, S.; van de Wijgert, J. Preferences and practices related to vaginal lubrication: Implications for microbicide acceptability and clinical testing. J. Womens Health 2005, 14, 424–433.
4. Pavelić, Ž.; Škalko-Basnet, N.; Jalšenjak, I. Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int. J. Pharm. 2005, 301, 140–148.
5. das Neves, J.; Bahia, M.F. Gels as vaginal drug delivery systems. Int. J. Pharm. 2006, 318, 1–14.
6. das Neves, J.; Amaral, M.H.; Bahia, M.F. Performance of an in vitro mucoadhesion testing method for vaginal semisolids: Influence of different testing conditions and instrumental parameters. Eur. J. Pharm. Biopharm. 2008, 69, 622–632.
7. das Neves, J.; da Silva, M.V.; Gonçalves, M.P.; Amaral, M.H.; Bahia, M.F. Rheological properties of vaginal hydrophilic polymer gels. Curr. Drug Deliv. 2009, 6, 83–92.
8. Geibel, S. Condoms and condiments: Compatibility and safety of personal lubricants and their use in Africa. J. Int. AIDS Soc. 2013, 16, 18531.
9. Voeller, B.; Coulson, A.H.; Bernstein, G.S.; Nakamura, R.M. Mineral oil lubricants cause rapid deterioration of latex condoms. Contraception 1989, 39, 95–102.
10. Fevola, M.J.; Gentner, L.; Ahmad, N.; Librizzi, J.J. Getting intimate with polymers: Personal lubricants. Cosmet. Toilet. 2008, 123, 59–68.
11. Nicole, W. A question for women’s health: Chemicals in feminine hygiene products and personal lubricants. Environ. Health Perspect. 2014, 122, A70–A75.
12. Maguire, R.A.; Bergman, N.; Phillips, D.M. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex. Transm. Dis. 2001, 28, 259–265.
13. Adriaens, E.; Remon, J.P. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex. Transm. Dis. 2008, 35, 512–516.
14. Moench, T.R.; Mumper, R.J.; Hoen, T.E.; Sun, M.; Cone, R.A. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect. Dis. 2010, 10, 331.
15. Begay, O.; Jean-Pierre, N.; Abraham, C.J.; Chudolij, A.; Seidor, S.; Rodriguez, A.; Ford, B.E.; Henderson, M.; Katz, D.; Zydowsky, T. et al. Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res. Hum. Retrovir. 2011, 27, 1019–1024.
16. Dezzutti, C.S.; Brown, E.R.; Moncla, B.; Russo, J.; Cost, M.; Wang, L.; Uranker, K.; Kunjara Na Ayudhya, R.P.; Pryke, K.; Pickett, J. et al. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One 2012, 7, e48328.
17. WHO/UNFPA/FHI. Use and Procurement of Additional Lubricants for Male and Female Condoms: WHO/UNFPA/FHI; WHO: Geneva, Switzerland, 2012.
18. Tien, D.; Schnaare, R.L.; Kang, F.; Cohl, G.; McCormick, T.J.; Moench, T.R.; Doncel, G.; Watson, K.; Buckheit, R.W.; Lewis, M.G. et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res. Hum. Retrovir. 2005, 21, 845–853.
19. Schwartz, J.L.; Ballagh, S.A.; Kwok, C.; Mauck, C.K.; Weiner, D.H.; Rencher, W.F.; Callahan, M.M. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007, 75, 136–141.
20. Garg, S.; Anderson, R.A.; Chany, C.J., II; Waller, D.P.; Diao, X.H.; Vermani, K.; Zaneveld, L.J. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 2001, 64, 67–75.
21. CurveExpert Basic 1.4. Available online: http://www.curveexpert.net/curveexpert-basic/ (accessed on 30 June 2014).
22. Owen, D.H.; Katz, D.F. A vaginal fluid simulant. Contraception 1999, 59, 91–95.
23. das Neves, J.; Michiels, J.; Ariën, K.K.; Vanham, G.; Amiji, M.; Bahia, M.F.; Sarmento, B. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm. Res. 2012, 29, 1468–1484.
24. Grimes, D.A.; Lopez, L.M.; Raymond, E.G.; Halpern, V.; Nanda, K.; Schulz, K.F. Spermicide used alone for contraception. Cochrane Database Syst. Rev. 2013, 12, CD005218.
25. Wu, J.P.; Fielding, S.L.; Fiscella, K. The effect of polycarbophil gel (Replens™) on bacterial vaginosis: A pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007, 130, 132–136.
26. Fiorilli, A.; Molteni, B.; Milani, M. Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: Results from a randomised double-blind, placebo-controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 120, 202–205.
27. Sobel, J.D. Vaginitis. N. Engl. J. Med. 1997, 337, 1896–1903.
28. Kaminsky, M.; Willigan, D.A. pH and the potential irritancy of douche formulations to the vaginal mucosa of the albino rabbit and rat. Food Chem. Toxicol. 1982, 20, 193–196.
29. Simões, J.A.; Bahamondes, L.G.; Camargo, R.P.; Alves, V.M.; Zaneveld, L.J.; Waller, D.P.; Schwartz, J.; Callahan, M.M.; Mauck, C.K. A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. Br. J. Clin. Pharmacol. 2006, 61, 211–217.
30. Sinha, A.; Ewies, A.A. Non-hormonal topical treatment of vulvovaginal atrophy: An up-to-date overview. Climacteric 2013, 16, 305–312.
31. Boskey, E.R.; Cone, R.A.; Whaley, K.J.; Moench, T.R. Origins of vaginal acidity: High D/L lactate ratio is consistent with bacteria being the primary source. Hum. Reprod. 2001, 16, 1809–1813.
32. Bonferoni, M.C.; Giunchedi, P.; Scalia, S.; Rossi, S.; Sandri, G.; Caramella, C. Chitosan gels for the vaginal delivery of lactic acid: Relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS PharmSciTech 2006, 7, 104.
33. Lacey, C.J.; Woodhall, S.; Qi, Z.; Sawant, S.; Cowen, M.; McCormack, S.; Jiang, S. Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial. Int. J. STD AIDS 2010, 21, 714–717.
34. Kutteh, W.H.; Chao, C.H.; Ritter, J.O.; Byrd, W. Vaginal lubricants for the infertile couple: Effect on sperm activity. Int. J. Fertil. Menopausal. Stud. 1996, 41, 400–404.
35. Agarwal, A.; Deepinder, F.; Cocuzza, M.; Short, R.A.; Evenson, D.P. Effect of vaginal lubricants on sperm motility and chromatin integrity: A prospective comparative study. Fertil. Steril. 2008, 89, 375–379.
36. Mahalingam, A.; Simmons, A.P.; Ugaonkar, S.R.; Watson, K.M.; Dezzutti, C.S.; Rohan, L.C.; Buckheit, R.W., Jr.; Kiser, P.F. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob. Agents Chemother. 2011, 55, 1650–1660.
37. Rohan, L.C.; Moncla, B.J.; Kunjara Na Ayudhya, R.P.; Cost, M.; Huang, Y.; Gai, F.; Billitto, N.; Lynam, J.D.; Pryke, K.; Graebing, P. et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010, 5, e9310.
38. Dezzutti, C.S.; Rohan, L.C.; Wang, L.; Uranker, K.; Shetler, C.; Cost, M.; Lynam, J.D.; Friend, D. Reformulated tenofovir gel for use as a dual compartment microbicide. J. Antimicrob. Chemother. 2012, 67, 2139–2142.
39. Grammen, C.; Arien, K.K.; Venkatraj, M.; Joossens, J.; van der Veken, P.; Heeres, J.; Lewi, P.J.; Haenen, S.; Augustyns, K.; Vanham, G. et al. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antivir. Res. 2014, 101, 113–121.
40. Decker, T.; Lohmann-Matthes, M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 1988, 115, 61–69.
41. Chen, J.; Geng, L.; Song, X.; Li, H.; Giordan, N.; Liao, Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: A multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J. Sex. Med. 2013, 10, 1575–1584.
42. Van Damme, L.; Ramjee, G.; Alary, M.; Vuylsteke, B.; Chandeying, V.; Rees, H.; Sirivongrangson, P.; Mukenge-Tshibaka, L.; Ettiegne-Traore, V.; Uaheowitchai, C. et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002, 360, 971–977.
43. Hillier, S.L.; Moench, T.; Shattock, R.; Black, R.; Reichelderfer, P.; Veronese, F. In vitro and in vivo: The story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 2005, 39, 1–8.
44. Gali, Y.; Delezay, O.; Brouwers, J.; Addad, N.; Augustijns, P.; Bourlet, T.; Hamzeh-Cognasse, H.; Ariën, K.K.; Pozzetto, B.; Vanham, G. In vitro evaluation of viability, integrity and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob. Agents Chemother. 2010, 54, 5105–5114.
45. Poudrier, J.K. Final report on the safety assessment of phenoxyethanol. J. Am. Coll. Toxicol. 1990, 9, 259–277.